Promising HIV treatments in early development – Part 2

AIDS awareness red ribbon, Alertness, Colour, Co-operation, Healthcare Medicine, HIV, Pin, Red, Ribbon, Single Object, Square, Studio Shot 

With our Exploratory Clinical Development World Europe conference fast approaching (22-24 May), I thought I would continue to touch on some of the interesting HIV treatments which have passed through Phase IIa and now entering later stage studies:

Entry Inhibitors

BMS-663068 – This early experimental drug demonstrated good antiviral activity in phase 2a, with the results announced at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) last year. This drug would be the first drug to target the attachment of HIV to the CD4 receptor to the cell by binding to the HIV-1 envelope glycoprotein gp120. We look forward to hearing the results from the phase 2b study from BMS!


CenicrivirocTobira Therapeutics began phase IIb trials of this potent antagonist of CCR5 and CCR2, last year. The 48-week comparative study is designed to evaluate the efficacy, safety and tolerability of cenicriviroc in 150 HIV-1-infected, antiretroviral treatment-naïve patients with only CCR5-tropic virus.


Integrase Inhibitors

Dolutegravir – This treatment is being developed as an option for treatment experienced patients who are resistant to Raltegravir or Elvitegravir. The phase 2b study showed response rates for 87% of all doses of dolutegravir over a 48 week trial. Phase 3 studies are now ongoing.



Lersivirine – This investigative drug matched Efavirenz at lowering HIV viral load in a phase 2b study, with the results announced at the International AIDS Society Conference in July 2011. This drug, being developed by ViiV Healthcare, has a unique binding pattern to HIV's reverse transcriptase enzyme, which enables it to remain active even with NNRTI resistance mutations (such as Y181 changes). Phase 3 studies are planned.


Finally, the latest NRTIs in phase II trials coming soon……………..

Leave a Reply

Your email address will not be published. Required fields are marked *